Skip to content
IPO Vista
GMP— what is the grey market premium?

Credent Connect N Care IPO

Credent Connect N Care Limitedc3logistics.co.in

ListedSMEHealth CareNSE Emerge
Price band
₹179 – ₹189

Face value ₹10.00

Issue size
₹93.90 Cr

100% fresh capital

Lot size
600 sh
Bidding
13 – 17 Aug

Lists 20 Aug 2026

Grey market
—

No quote recorded

Market data to 30 Oct 2026. Company figures are as filed, sourced 16 Oct 2026. Every figure’s origin is listed under Sources.

The question this issue poses

In one sentence

Credent Connect N Care runs outsourced field operations for India's diagnostic laboratory industry — specimen collection, temperature-controlled transport, and phlebotomy and paramedical staff stationed inside client laboratories and hospitals. The prospectus records 2,530 associated laboratories at 31 March 2026, against 2,256 a year earlier and 1,675 in 2024, and 6,338 people at 31 March 2026 (4,052 on payroll, 2,286 on contract). Revenue from operations was Rs 75.73 Cr in FY24, Rs 77.94 Cr in FY25 and Rs 214.16 Cr in FY26, the last a rise of 174.78%, with EBITDA margin on those figures of 5.68%, 6.40% and 13.29%. The Rs 93.90 Cr issue was entirely fresh, priced at Rs 179-189, and was subscribed 153.13 times overall on the closing day; it listed on NSE Emerge at Rs 359.10 against the Rs 189 band top, closed day one at Rs 377.05, and last traded at Rs 313.90 on 23 October 2026.

IPOVista score

How this issue scores, and why

Every pillar opens to show the raw metric, the curve it was mapped through, the sub-score and its weight. Disagree with the weighting if you like — the arithmetic is all here.

84Exceptional
IPOVista score 84 out of 100, graded Exceptional.

IPOVista score

Broadly well-balanced

63% of the scoring model was backed by disclosed data for Credent Connect N Care, giving medium confidence. Weights for anything missing were redistributed rather than scored as zero.

How this score is built
PillarScoreWeight

Below the line: market sentiment. Capped at 8 of 100 points so a hot grey market can tilt a score but never carry one.

Read this before the number

  • SME platform listing

    SME issues trade in larger lot sizes with thinner volumes than mainboard listings, which makes exiting a position harder.

The IPOVista Score is a transparent summary of disclosed fundamentals and issue terms. It is research, not investment advice, and it cannot predict listing performance.

The company

What the business actually does

Founded 2015 · New Delhi, Delhi, India · 6,338 employees

Credent Connect N Care runs outsourced field operations for India's diagnostic laboratory industry. It collects blood, urine and other specimens from patients' homes and from collection centres using trained phlebotomists, moves them to testing laboratories under temperature-controlled and turnaround-time-bound conditions, and stations its own phlebotomy teams, laboratory technicians and paramedical staff inside client laboratories and hospitals. It also operates inter-state and intra-state sample logistics. Customers are diagnostic chains, in-vitro diagnostics firms, pharmaceutical companies, clinics and hospitals. The prospectus records 2,530 associated laboratories as of 31 March 2026, against 2,256 a year earlier and 1,675 in 2024. The business began in 2015 as Credent Cold Chain Logistics and had 6,338 people at 31 March 2026 — 4,052 on payroll and 2,286 on contract.

Revenue is service fees billed to laboratories and hospitals on credit terms, for sample pickup and transport and for manpower deployed on their premises. The cost base is people and vehicles: in FY26 employee benefit expenses were Rs 84.61 crore and cost of materials and services Rs 73.18 crore, against revenue from operations of Rs 214.16 crore. Those costs are largely fixed against client testing volumes, so margin tracks utilisation — the prospectus reports EBITDA margin of 13.29% in FY26 versus 6.41% in FY25. Two structural constraints: customer concentration, with the top ten customers at 81.76% of FY26 revenue, and working capital, with trade receivables of Rs 58.83 crore at 31 March 2026.

The company on paper

Legal name
Credent Connect N Care Limited
IncorporatedThe legal entity is often incorporated years before the brand you know, and may have traded under another name first
25 Jun 2015
CINCorporate Identity Number — the unambiguous handle for looking this company up at the MCA
U63000DL2015PLC281994
Sector
Health Care · Healthcare logistics and outsourced field services for diagnostic laboratories
Employees
6,338
Registered office
New Delhi, Delhi, India
Promoters
Ashok Kumar Sharma, Karan Sharma, Tarun Sharma, Dimple Sharma, Tanveen
Promoter holding, pre-issue
87.5%
Promoter holding, post-issue
63.7%

The numbers

Financial performance

Revenue has compounded at 68.2% a year across the 3 reported financial years.

Revenue and profit

Figures in ₹ crore, as reported in the prospectus. Interim quarters are not annualised.

  • Revenue
  • Profit after tax

Margin trend

Profit and operating margin as a percentage of revenue

  • Net margin
  • EBITDA margin

Net worth and borrowings

At each period end, in ₹ crore. Gearing below each period is borrowings over net worth, from these same figures.

  • Net worth
  • Total borrowings

The price

Valuation

What the issue asks for the business, set against what the business earns.

No valuation ratios are recorded for this issue. The price band and the reported financials above are what this record holds.

The terms

How the issue is structured

100% of the money raised is fresh capital that goes to the company; the rest goes to shareholders selling down.

Fresh issueNew shares — proceeds go to the company
₹93.90 Cr
Offer for saleExisting shares — proceeds go to the selling shareholders
₹0
Total issue size
₹93.90 Cr
Shares offered in the OFS
—
Pre-issue shares outstanding
—
Employee discount
—
Market maker portionSME issues require a market maker to provide two-way quotes
2,52,000

What the issue does to ownership

Share of paid-up equity before and after the offer. The promoters give up 23.8% of the company.

  • Promoters
  • Everyone else
Before88%12%After64%36%

Hover or focus a segment to see who it is. The two bars are the same company, measured before and after the offer.

Percentages are of paid-up equity, and the “after” column assumes the offer is fully subscribed, which is how the offer document states it. This record does not disclose a pre- and post-issue share count, so the part of the company actually changing hands is not split out — everyone who is not a promoter is shown together.

Demand

What the market is bidding

Subscription is hard exchange data. Grey-market premium is not — it is an unofficial quote, shown because readers want it and labelled because it deserves the label.

Subscription by category

Cumulative bid multiples at the end of day 3. Anchor allocations are excluded.

QIB130.40×NII / HNI216.97×Retail138.86×

Hover or focus a category to see who bids in it.

Total subscription153.13×

A category subscribed above 1× is oversubscribed; allotment in that category then runs as a lottery or on a proportionate basis.

Grey market premium

Unofficial over-the-counter sentiment

No grey-market quotes have been recorded for this issue.

Outcome

How it actually listed

Issue price
₹189.00
Listed at
₹359.10
Listing gain
up 90.0%
Since listing
up 10.4%

Trading at ₹396.35 on 30 Oct 2026

Against the issue price
up 109.7%

What an allotment is worth now, before costs

Work it out

What this means for one application

Three calculations, each stating the assumption it rests on.

What one application costs

Shares are applied for in whole lots at the cut-off price. The full amount is blocked in your bank account under ASBA, not debited, until allotment.

Lots
2 lots, 1200 shares, ₹2,26,800 blocked
Shares applied for
1,200
At cut-off price
₹189.00
Amount blocked
₹2,26,800

One lot is 600 shares at ₹1,13,400. This issue requires a minimum of 2 lots, so the smallest application is ₹2,26,800. That is how the SME board is built rather than a quirk of this issue: the minimum application is set above the ₹2,00,000 that caps a retail bid on the mainboard — two lots rather than one. The smallest bid here still sits in the individual investors’ category, the one the subscription figures call retail, and when that category is oversubscribed the minimum application is allotted by draw of lots — so the odds beside this apply directly.

Odds of getting an allotment

When the retail category is oversubscribed, SEBI requires a lottery for the minimum lot. Every application has the same chance, whatever its size.

~0.7%

chance of one lot, per application

Retail subscription
138.86×
Applicants per share available
138.9× the retail quota

This is an estimate of a lottery, not a prediction. Actual odds depend on the final basis of allotment, how many applications were at the minimum lot, and rejections for technical reasons. Applying from multiple distinct PANs is the only legitimate way to hold more tickets in that lottery.

What it actually did

This issue has listed, so there is a real number instead of a prediction. The grey-market premium is shown beside it for comparison.

₹359.10

listed at, 90.0% against the issue price

Issue price
₹189.00
Premium said
—
If allotted 600 shares
₹1,02,060

Listing-day figures are as reported by the exchanges.

Our read

The case for and against

Grounded only in figures disclosed in the prospectus. This is analysis, not a recommendation.

What works

  • Revenue and EBITDA were higher in each successive year on record: revenue Rs 75.73 Cr in FY24, Rs 77.94 Cr in FY25 (up 2.92%) and Rs 214.16 Cr in FY26 (up 174.78%); EBITDA Rs 4.30 Cr, Rs 4.99 Cr (up 16.05%) and Rs 28.46 Cr (up 470.34%).
  • EBITDA margin was 5.68% in FY24 (Rs 4.30 Cr on Rs 75.73 Cr), 6.40% in FY25 (Rs 4.99 Cr on Rs 77.94 Cr) and 13.29% in FY26 (Rs 28.46 Cr on Rs 214.16 Cr) — higher in each later year. The prospectus states the FY26 and FY25 figures as 13.29% and 6.41%.
  • The whole Rs 93.90 Cr issue was fresh capital, with an offer for sale of nil, raised against a 31 March 2026 net worth of Rs 43.79 Cr — 2.14 times that net worth.
  • The prospectus records a base of 2,530 associated laboratories at 31 March 2026, 2,256 at 31 March 2025 and 1,675 in 2024: higher at each date on record, by 34.69% and then 12.15%.

What to weigh against it

  • Customer concentration: the prospectus puts the top ten customers at 81.76% of FY26 revenue.
  • Profit after tax did not move in step with revenue across the record. It was Rs 2.66 Cr in FY24 and Rs 2.25 Cr in FY25, a fall of 15.41%, on revenue 2.92% higher at Rs 77.94 Cr against Rs 75.73 Cr; it then reached Rs 18.45 Cr in FY26. PAT margin ran 3.51%, 2.89% and 8.62% on those revenues.
  • Working capital is tied up in receivables: trade receivables were Rs 58.83 Cr at 31 March 2026 against FY26 revenue from operations of Rs 214.16 Cr — 27.47% of that year's revenue, or roughly 100 days of it. The record carries no receivables figure for FY24 or FY25, and no operating cash flow for any year.
  • Two cost lines the prospectus quantifies for FY26 — employee benefit expenses of Rs 84.61 Cr and cost of materials and services of Rs 73.18 Cr — total Rs 157.79 Cr, or 73.68% of revenue from operations of Rs 214.16 Cr. The record carries no equivalent split for FY24 or FY25.

Easy to miss in the prospectus

  • The FY26 figures are a single year and the last period on record: revenue Rs 214.16 Cr against Rs 77.94 Cr in FY25, EBITDA Rs 28.46 Cr against Rs 4.99 Cr, PAT Rs 18.45 Cr against Rs 2.25 Cr. The record holds no period after 31 March 2026.
  • Borrowings were Rs 6.85 Cr at FY24, Rs 7.42 Cr at FY25 and Rs 21.95 Cr at FY26, the last a rise of 195.82%; net worth over the same dates was Rs 13.66 Cr, Rs 15.90 Cr and Rs 43.79 Cr, leaving borrowings at 0.50x, 0.47x and 0.50x of net worth.
  • The price has fallen back since listing day: Rs 359.10 at listing, Rs 377.05 at the day-one close, and Rs 313.90 on 23 October 2026 — 16.75% below the day-one close, 12.59% below the listing price, and 66.08% above the Rs 189 band top.

Straight from the filing

Read it yourself

Every figure on this page comes out of these. Go and check them.

Served by the issuer, the exchange or the regulator — never a copy hosted here, so what you open is the filing itself.

The paperwork

Who is running the issue

Lead managers
Hem Securities Limited
RegistrarAllotment status is checked on the registrar's own site
KFin Technologies Limited

How these figures were checked

Reconciled to Credent Connect N Care's own prospectus and to exchange disclosures, then cross-checked against 6 other independently published compilations of the same filing. Where a stated ratio disagreed with the line items it should come from, the disagreement was settled against the prospectus itself.

The prospectus is the authoritative document. Check anything that matters against it before you act.

Other issues worth reading next

Pramodini Medicare

Diagnostic imaging and pathology centres operated inside partner hospitals

Listed 19 Aug 2026 · SME

Price band
₹110 – ₹118
Listing gain
up 1.7%
Score
86/100

ABH Healthcare

Multi-specialty tertiary care hospital in small-city Punjab

Listed 1 Sep 2026 · SME

Price band
₹96 – ₹102
Listing gain
down 2.9%
Score
57/100

Himalaya Nutravedics

Ayurvedic and nutraceutical formulations, own-brand plus third-party contract manufacturing

Listed 29 Sep 2026 · SME

Price band
₹100 – ₹106
Listing gain
up 11.3%
Score
86/100